Laboratory evaluation of Abiraterone, a novel small molecule inhibitor of androgen synthesis that is safe, and has durable clinical antitumour activity in prostate cancer patients who have failed standard androgen deprivation therapy.

Johann de Bono, Gerhardt Attard, Jeremy Clark, Gyula Kovacs, Michelle Garrett, Mitch Dowsett, Florence Raynaud, David Dearnaley, Chris Parker and Colin Cooper, Institute of Cancer Research

Prognostic markers from the analysis of mechanisms of genetic predisposition to human prostate cancer

Prof Colin Cooper, Dr Rosalind Eeles, Dr Zsofia Kote-Jarai, Dr Amanda Swain, Institute of Cancer Research

Relevance of Interleukin-8 and c-FLIP in promoting resistance to anti-androgen therapy and as biomarkers of elevated risk of androgen-independence in prostate cancer

Dr David Waugh, Dr Jo O'Sullivan & Dr Daniel Longley, Queen's University, Belfast

Effect of IGF receptor inhibition on sensitivity of prostate cancer to DNA damaging cancer treatments

Dr Valentine Macaulay & DPhil student Kunal Lodhia, Weatherall Institute of Molecular Medicine, Oxford

The role and regulation of glycogen synthase kinase-3 in prostate cancer

Dr Robert Kypta, CIC bioGUNE, Spain

Protein-glycan interactions in the regulation of the immune privilege in prostate cancer

Gabriel Rabinovich, Diego Laderach, Daniel Compagno, Mariana Salation & Marta Toscano, Instituto de Biologia y Medicina Experimenta, Argentina

Pharmacological perturbation of p68 - an important androgen receptor transcriptional co-regulator in prostate cancer

Prof Craig Robson & Dr Emma Clark, Northern Institute for Cancer Research (NICR), Newcastle University

The progression to prostate cancer - a role for the novel growth-promoting cytokines pleiotrophin (PTN) and midkine (MK) in prostate stromal and epithelial cell proliferation and the regulation of protein kinases B and C

Dr Martin Rumsby, University of York